Two of these laws are the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Both of these acts allow the FDA to waive research for some drugs already used in adults, such as some cancer drugs. In 2010, PhRMA spent $22 million on lobbying on health care issues. Thanks to the work of more than 50 lobbyists, laws beneficial to its pharmaceutical clients have been passed. In exchange for their support of Obamacare, it is believed that PhRMA will receive preference on future policies that will be worth billions to the industry (Blaine). Additionally, laws such as the Food and Drug Administration Safety and Innovation Act limit foreign competition and counterfeit drugs, which will increase PhRMA companies' profits.